Has Juan Granada received payments from drug or device companies?

Yes. Drug and device makers reported $4,065,285 in general payments to Juan Granada across 156 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Juan Granada did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Juan Granada come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Juan Granada

Interventional Cardiology · Houston, TXNPI 1831175363

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $3,919,738 of the $4,065,285 with a category attached, or 96.4%. Cephea Valve Technologies, Inc. accounts for 96.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $3,412,323 and has fallen 97.8% since, to $73,451 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,065,285in general payments, 2019–2025

Across 156 payments — averaging $26,060 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Cephea Valve Technologies, Inc.$3.9M
Abbott$136K
Medtronic$5K
Boston Scientific$5K
Edwards Lifesciences$64
Siemens Medical Solutions USA, Inc.$55

$235,602in research payments, 2019–2025

Across 3 payments — averaging $78,534 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$236K

What the payments were for

Consulting fees$114,8753%
Speaking & faculty fees$2,0000%
Grants$550%
Travel & lodging$25,0241%
Food & beverage$3,5930%
Ownership interest$3,919,73896%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Cephea Valve Technologies, Inc.	3	$3,919,738
Abbott	133	$135,607
Medtronic(2 entities)	8	$5,270
Boston Scientific	9	$4,551
Edwards Lifesciences	2	$64
Siemens Medical Solutions USA, Inc.	1	$55

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,065,285 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas →

Other interventional cardiology in Houston

John IsaacHouston$1.8M
Sanjay KunapuliHouston$267K
Michele SartoriHouston$266K
Abhijeet DhobleHouston$161K
Amir KashaniHouston$148K
Dhaval ParekhHouston$137K
Neal KleimanHouston$118K
Mehran MassumiHouston$114K
Eduardo HernandezHouston$112K
Salman ArainHouston$108K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →